New agent treats symptoms of urinary tract conditions

August 26, 2010

Mission Pharmacal Co. has announced the introduction of methenamine, sodium phosphate monobasic, phenyl salicylate, methylene blue, hyoscyamine sulfate (Uribel) capsules for oral administration to help relieve local discomfort and inflammation associated with lower urinary tract infections, interstitial cystitis, painful bladder syndrome, and pre- and post-diagnostic urinary tract procedures.

Mission Pharmacal Co. has announced the introduction of methenamine, sodium phosphate monobasic, phenyl salicylate, methylene blue, hyoscyamine sulfate (Uribel) capsules for oral administration to help relieve local discomfort and inflammation associated with lower urinary tract infections, interstitial cystitis, painful bladder syndrome, and pre- and post-diagnostic urinary tract procedures.

Unlike single-agent analgesic therapies, the treatment relieves urinary tract symptoms with five integrated analgesic, antispasmodic, and antiseptic ingredients that work together to alleviate pain and spasms and eliminate bacteria, according to Mission Pharmacal, which will handle distribution and marketing of the drug for Star Pharmaceuticals, LLC.

The drug may be used in conjunction with antibiotic therapies or other medicines, and are prescribed as one capsule orally four times per day followed by liberal amounts of fluid. Symptom relief can begin within 30 minutes, and there is no restriction on the length of therapy. The components are generally well tolerated, well-absorbed from the gastrointestinal tract, and excreted from the urine in 12 to 24 hours.